Form 8-K BIOGEN INC. For: Feb 03
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/21/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- Tesla acquires AI hardware company for up to $2 billion in stock
- Bel Fuse acquires dataMate ethernet business for $16 million
- Fed: Nine Of 18 FOMC Participants Pencil In 2026 Rate Hike
Biogen (BIIB) Misses Q4 EPS by 29c, Guides FY Below Consensus
February 3, 2021 7:08 AM EST(Updated - February 3, 2021 7:09 AM EST)
Biogen (NASDAQ: BIIB) reported Q4 EPS of $4.58, $0.29 worse than the analyst estimate of $4.87. Revenue for the quarter came in at $2.85 million versus the consensus estimate of $2.8 million.
GUIDANCE:
Biogen sees FY2021 EPS of $17.00-$18.50, versus the consensus of $24.67. Biogen sees FY2021 revenue of $10.45-10.75 billion, versus the consensus of $11.22 billion.
Biogen expects full year 2021 revenue to be between $10.45 billion and $10.75 billion, Non-GAAP diluted EPS to be between $17.00 and $18.50, and capital expenditures to be between $375 million and $425 million.This financial... More
